A Study to Explore Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma


About this study

The purpose of this study is to identify gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA), and to determine the composition of immune cells present in the microenvironment of individuals with SEA after initiation of mepolizumab.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Diagnosis of SEA by a health care provider
  • History of an absolute eosinophil count ≥ 300/mm^3
  • Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started

Exclusion Criteria:

  • Age < 18 years old.
  • Pregnancy.
  • Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
  • Currently using or any prior use of rituximab.
  • History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
  • Any prior history of malignancy, autoimmune disease, or immune deficiency.
  • Any other significant medical issue as determined by the principal investigator.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thanai Pongdee, M.D.

Open for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.

(507) 284-5689


More information


Publications are currently not available